How 3D genomic testing from Fox Chase Cancer Center could change the way cancer is diagnosed
Fox Chase Cancer Center and Arima Genomics have partnered to bring advanced 3D genomic testing into clinical practice, aiming to improve cancer diagnosis and treatment. This partnership will enable the use of Arima's Hi-C based technology to analyze the 3D structure of DNA, providing more accurate insights into tumor formation and evolution.
Fox Chase Cancer Center and Arima Genomics have partnered to integrate 3D genomic testing into clinical practice. The partnership will utilize Arima's Hi-C based technology to analyze the 3D structure of DNA. This technology will be used to improve diagnosis and treatment of lymphoma and sarcoma. The Cancer Epigenetics Institute will leverage Arima's Aventa tests to identify genomic changes that traditional testing methods may miss. The collaboration will also enable cutting-edge research to identify new drug targets and understand cancer biology. This partnership marks the first time a leading cancer center has partnered with Arima to integrate clinical testing and research at scale.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.